Groningen, the Netherlands — 02 February 2026
InnoCore Pharmaceuticals announced the appointment of Hans de Backer as its new Chief Executive Officer today. Hans joins the company with a proven track record as a strategy‑driven business leader, recognized for delivering sustainable growth, shepherding complex organizations, and building energized, high‑performance teams.
Hans previously held senior leadership roles at Aspen Pharmacare and Biosynth, where he successfully scaled life‑sciences and manufacturing businesses across multiple international markets. His experience spans commercial leadership, operational excellence, strategic partnerships, and business transformation.
Hans’s appointment as CEO of InnoCore reflects and reinforces the company’s ambition to become the go‑to partner for long-acting injectables (LAI) development for biologics and peptides. With the rapid global expansion of biologics and peptide therapeutics, demand for advanced LAI drug delivery technologies is on the rise. InnoCore aims to meet this demand and thus realize its mission to improve patient health and treatment convenience.
At the helm of InnoCore’s next growth phase, Hans will oversee the strategic execution of:
Strengthening operational and development capabilities.
InnoCore Pharmaceuticals is a Netherlands‑based drug development company specializing in long‑acting injectable (LAI) formulations using proprietary biodegradable polymer technologies. The company partners with global pharmaceutical and biotech companies to develop innovative, patient‑friendly LAI solutions for biologics, peptides, and small molecules.